N/A N=558 Feasibility Trial of the iAMHealthy Intervention
Obesity; Rurality
Primary: Participant Recruitment Rate — 99; 5 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 ECG Belt to Assess Electrical Synchronization
Bradycardia · Heart Failure
Primary: • ECG Belt Analysis of Standard Deviation of Activation Times (SDAT) of LBBP Compared to Native Conduction — 38.6; 20.5 ms
N/A N=20 Virtual Reality for Improving Pain and Distress in Patients With Advanced Stage Colorectal Cancer
Colorectal Cancer
Primary: Feasibility, Assessed by Examining Number of Participants Accrued — 20 Participants
Phase 3 N=445 A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Maximum Observed Serum Concentration (Cmax) of Adalimumab — 9.156; 8.974 Micrograms per milliliter
Phase 2 N=52 AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL)
Breast Cancer
Primary: Number of Participants With Serious Adverse Events (SAEs) — 10 Participants
Phase 2 N=26 GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
Neoplasms
Primary: Number of Participants With Dose Limiting Toxicities (DLTs)-Part 1 — 0; 0; 0; 0 Participants
N/A N=25 Contact Lens Adaptation in Neophytes
Contact Lens Comfort
Primary: Between-Group Difference in Eye Comfort as Measured by the Ocular Surface Disease Index (OSDI) — 10.8; 16.3 Units on a Scale — p=0.83
Phase 2 N=88 Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)
Renal Cell Carcinoma, Metastatic
Primary: Overall Survival (OS) - Days (FAS) — 323; 282; 1270; 1099 days — p=0.964
Phase 3 N=643 Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)
HIV Infection
Primary: Percentage of Participants With Human Immunodeficiency Virus 1 Ribonucleic Acid (HIV-1 RNA) ≥50 Copies/mL at Week 48 — 0.6; 0.3; 5.6; 5.3 Percentage of Participants…
N/A N=40 ED-Home Pilot Study
Housing Problems · Drug Use · Alcohol; Use, Problem
Primary: Percentage of Potential Participants Approached Who Were Eligible for the Study — 2.34 Percentage of Participants
N/A N=29 Postnatal mHealth Intervention Development
Health Attitude · Knowledge, Attitudes, Practice · Postpartum Depression
Primary: Satisfied or Very Satisfied About Their Overall Intervention Experience — 29 Participants
N/A N=12 Stimulation With Wire Leads to Restore Cough
Spinal Cord Injuries · Spinal Cord Diseases · Paralysis
Primary: Measurements of Peak Expiratory Airflow Rate to Evaluate Efficacy of Cough. — 2.1; 9.6; 10.4; 11.1 L/s — p=<0.05
Phase 3 N=928 Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity
Squamous Cell Carcinoma of the Oral Cavity · Squamous Cell Carcinoma of the Soft Palate
Primary: Overall Survival (OS) — 46.3; 58.1; 52.9 months — p=0.4051
Early Phase 1 N=6 Galantamine and CBT4CBT Pilot to Prevent Relapse.
Methadone or Buprenorphine Detoxoxification
Primary: Change in Methadone/Buprenorphine Dose to 0 mg for Successful Completion of Taper — 3; 2 Participants
Phase 3 N=520 A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine
Episodic Migraine
Primary: Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days (MHDs) During the Double-blind Treatment Phase. — -1.99; -3.81 days per month — p=<.0001